ClariVest Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

ClariVest Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-64,467	Closed	-$150K	–	748
2018 Q1	$150K	Buy	64,467 +6,265	+11%	+$14.7K	﹤0.01%	631
2017 Q4	$110K	Hold	58,202	–	–	﹤0.01%	624
2017 Q3	$145K	Buy	58,202 +2,258	+4%	+$5.6K	﹤0.01%	520
2017 Q2	$153K	Hold	55,944	–	–	﹤0.01%	503
2017 Q1	$169K	Buy	+55,944	New	+$159K	﹤0.01%	504

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

ClariVest Asset Management's LCTX Position: Q2 2018 in Review

ClariVest Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2018, closing a stake of 64,467 shares — an estimated $150K sold.

ClariVest Asset Management first reported a position in LCTX in Q1 2017 and held it in 5 quarters. The position peaked at $169K in Q1 2017. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2018.

ClariVest Asset Management reported no remaining Lineage Cell Therapeutics position as of Q2 2018 after selling out during the quarter.
ClariVest Asset Management sold 64,467 Lineage Cell Therapeutics shares in Q2 2018, an estimated $150K.
ClariVest Asset Management first reported a position in Lineage Cell Therapeutics in Q1 2017 and held it in 5 quarters.
ClariVest Asset Management's Lineage Cell Therapeutics position peaked at $169K in Q1 2017.
107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2018.

Based on ClariVest Asset Management's 13F filing for Q2 2018, filed 10 Aug 2018.